List of Excipients in Branded Drug PAZOPANIB

Generic Drugs Containing PAZOPANIB

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	pazopanib	0480-4184	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals Inc	pazopanib	0480-4184	FERROSOFERRIC OXIDE
Teva Pharmaceuticals Inc	pazopanib	0480-4184	HYPROMELLOSE 2910
Teva Pharmaceuticals Inc	pazopanib	0480-4184	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in PAZOPANIB?

# Of NDCs	Excipient
8	CELLULOSE, MICROCRYSTALLINE
1	FERRIC OXIDE YELLOW
6	FERROSOFERRIC OXIDE
2	HYDROXYPROPYL CELLULOSE

Pazopanib Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 3, 2026

Pazopanib is a poorly water-soluble, orally administered tyrosine kinase inhibitor whose commercial formulation depends on controlling dissolution, gastric exposure, tablet robustness, and food-effect variability. The strongest excipient opportunities are improved solubilization, pediatric or dysphagia-friendly dosage forms, lower-dose titration, and formulations that reduce variability without infringing active-ingredient, polymorph, or method-of-use claims.

Votrient is a film-coated immediate-release tablet containing pazopanib hydrochloride. Its core uses conventional excipients, including microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate. The product is taken without food because food substantially increases exposure. That restriction creates a commercial opening for food-effect reduction, liquid delivery, and more predictable absorption.[1]

Pazopanib is a small molecule, so biosimilar competition does not apply. Competition is expected through abbreviated new drug applications, 505(b)(2) products, formulation improvements, and potentially licensed or authorized generics.

What is the current pazopanib formulation?

Votrient contains pazopanib hydrochloride equivalent to 200 mg or 400 mg of pazopanib. The product is supplied as an immediate-release film-coated tablet.[1]

What excipients are used in Votrient tablets?

The publicly listed tablet excipients include:

Formulation function	Excipient used in Votrient
Diluent and compression aid	Microcrystalline cellulose
Binder	Povidone
Disintegrant	Sodium starch glycolate
Lubricant	Magnesium stearate
Film coating	Hypromellose-based coating system, with colorants and polyethylene glycol-type plasticizer components

The formulation is conventional from a tableting perspective. Its technical challenge is the active ingredient rather than an unusually complex excipient system. Pazopanib hydrochloride has low aqueous solubility, and dissolution is sensitive to pH. A generic developer must reproduce adequate release and bioequivalence while managing powder flow, compression, coating, stability, and manufacturing scale-up.

What are the key biopharmaceutical constraints?

The principal constraints are:

1. Low intrinsic solubility and pH-dependent dissolution.
2. A clinically relevant food effect.
3. The need for consistent exposure across patients.
4. Potential sensitivity to particle size, crystal form, wetting, and gastrointestinal precipitation.
5. A narrow commercial tolerance for formulation changes because the reference product is an established tablet.

The FDA label reports that administration with a high-fat meal approximately doubles pazopanib exposure, while a low-fat meal increases exposure by roughly 1.7-fold compared with fasting administration.[1] That effect is a direct target for excipient and delivery-system innovation.

What excipient strategies are most relevant for pazopanib?

The most commercially relevant strategies are amorphous stabilization, wetting enhancement, pH modification, particle engineering, and lipid-based solubilization.

Amorphous solid dispersions

An amorphous solid dispersion can improve apparent solubility by dispersing pazopanib at a molecular or near-molecular level within a polymeric carrier. Candidate polymers include:

• Hypromellose acetate succinate
• Hypromellose phthalate
• Polyvinylpyrrolidone
• Copovidone
• Soluplus-type graft copolymers
• Polyethylene oxide or related polymeric matrices

The principal development risk is recrystallization during storage or after gastrointestinal dilution. A successful product would require comparative crystallinity testing, moisture control, dissolution profiling across pH conditions, and long-term stability data.

A patent strategy could claim the active-polymer ratio, manufacturing process, residual solvent limits, glass-transition characteristics, dissolution profile, or stabilized amorphous form. These claims may create a more defensible position than a broad claim to a conventional tablet.

Surfactant and wetting systems

Surfactants can improve wetting and dispersion of pazopanib particles. Potential options include sodium lauryl sulfate, polysorbates, poloxamers, and nonionic lipid-compatible surfactants.

The main limitations are gastrointestinal tolerability, oxidative stability, compatibility with the tablet matrix, and the risk that increased dissolution in vitro will not translate into improved or more consistent exposure in vivo.

A low-level surfactant system may be commercially attractive when the target is bioequivalence rather than a large increase in bioavailability. It can reduce dependence on very small particle size and improve manufacturing robustness.

pH modifiers and microenvironmental pH control

Pazopanib dissolution can be improved by creating a favorable microenvironment within the dosage form. Acidifying agents, buffering salts, or alkaline modifiers can alter local pH around the drug particles.

Potential excipient classes include citric acid, fumaric acid, tartaric acid, sodium citrate, phosphate buffers, and carbonate systems. The selection must account for:

• Chemical stability
• Moisture uptake
• Tablet hardness
• Gastric irritation
• Compatibility with the hydrochloride salt
• Impact on dissolution after gastric emptying

A pH-modified formulation can be patentable if the claims link the excipient system to a defined dissolution profile, exposure range, or reduced food effect.

Particle-size reduction and wet milling

Micronization, nanocrystal formation, and wet milling can increase surface area and accelerate dissolution. These approaches are familiar to generic manufacturers and may be easier to scale than a sophisticated dispersion system.

The commercial weakness is that particle-size reduction alone may not eliminate the food effect. It can also increase cohesion, electrostatic charging, dusting, and agglomeration. The most effective approach may combine particle engineering with a wetting agent, polymeric stabilizer, or protective coating.

Lipid-based formulations

Self-emulsifying drug delivery systems, lipid suspensions, and soft-gel formulations can address poor solubility and potentially reduce dependence on gastric dissolution. Medium-chain triglycerides, long-chain lipids, surfactants, and cosolvents are possible components.

These systems carry higher development and manufacturing complexity than tablets. They may have commercial value where improved absorption, reduced variability, or an alternative dosage form justifies a 505(b)(2) pathway.

Multiparticulates and liquid formulations

A suspension, granule, powder-for-reconstitution, or sprinkle product could address swallowing difficulty, dose flexibility, and administration in specialty-care settings.

A liquid product would need control of:

• Sedimentation and redispersibility
• Chemical and physical stability
• Taste and mouthfeel
• Preservative compatibility
• Dose-measuring accuracy
• Container closure performance

Pazopanib is not an obvious pediatric opportunity because its approved indications are primarily adult oncology uses. The stronger commercial rationale is dysphagia, feeding-tube administration, dose modification, and patients unable to swallow conventional tablets.

What formulations are protected by pazopanib patents?

The foundational pazopanib compound is associated with U.S. Patent No. 6,258,812, which covers pyrimidine derivatives with kinase-inhibitory activity, including pazopanib-related subject matter.[2] Later patent activity has included pharmaceutical compositions, solid forms, and manufacturing or formulation concepts.

The relevant protection categories are:

Protection category	Commercial significance
Compound claims	Can block products containing the protected active ingredient during the patent term
Salt and solid-form claims	Can restrict use of a specified pazopanib hydrochloride form
Composition claims	Can cover excipient combinations, ratios, or dosage-form architecture
Method-of-use claims	Can affect products labeled for protected indications or dosing regimens
Manufacturing claims	Can create barriers where the process is necessary to obtain the claimed form
Dissolution or exposure claims	Can support differentiated 505(b)(2) or formulation products

The practical value of an excipient patent depends on claim scope. A claim limited to a narrow polymer ratio may be easier to design around than a claim covering a broad class of solubilizers. Conversely, broad composition claims may face enablement, written-description, obviousness, or anticipation challenges.

What is the FDA and Orange Book status of pazopanib?

Pazopanib was approved by the FDA as Votrient for advanced renal cell carcinoma and advanced soft tissue sarcoma in specified patient populations.[1] The reference product is listed in the FDA Orange Book under pazopanib hydrochloride tablets.

Because pazopanib is a small molecule, ANDA applicants can pursue generic approval by demonstrating pharmaceutical equivalence and bioequivalence. An applicant generally does not need to reproduce every excipient used by Votrient, but it must meet applicable quality, performance, labeling, and bioequivalence requirements.

What Paragraph IV risks exist for pazopanib?

Paragraph IV risk depends on the current Orange Book patent listings, patent expiration dates, pediatric extensions, and any litigation or settlement agreements. The core commercial issues are:

• Whether an applicant challenges listed patents before expiry.
• Whether the applicant uses a certification that no listed patent is infringed.
• Whether the reference sponsor files an infringement action within the statutory period.
• Whether a 30-month stay applies.
• Whether a first-filer could obtain 180-day generic exclusivity.
• Whether formulation patents remain after compound-patent expiry.

A generic tablet that uses the same active ingredient but different excipients may avoid composition claims while still facing solid-form or method-of-use patents. A formulation developer should perform a claim chart against every Orange Book-listed patent and relevant unlisted patent family before selecting the excipient platform.

When does pazopanib lose exclusivity?

The primary compound patent has historically been the central exclusivity barrier, but commercial launch timing depends on the full patent and regulatory record rather than one expiration date. Regulatory exclusivity and patent exclusivity must be analyzed separately.

Exclusivity element	Relevance to pazopanib
New chemical entity exclusivity	Delayed ANDA submission during the statutory period
Orphan-drug exclusivity	May apply to a specific approved indication if granted
Pediatric exclusivity	Can add six months to qualifying listed patents and exclusivities
Compound patent	Historically the principal barrier to generic entry
Solid-form or formulation patents	May delay or complicate entry after compound expiry
Method-of-use patents	Can require carve-outs from generic labeling
Litigation stays	Can delay approval or launch after a Paragraph IV notice

Generic entry often begins with a “skinny label” strategy when protected indications or dosing methods can be omitted. That approach is less effective where the protected method is inseparable from the principal commercial use.

How strong is the pazopanib patent estate?

The estate is strongest where claims cover the active compound or a necessary solid form. Excipient-only claims are generally narrower and more vulnerable to design-around strategies.

Strengths

• Established small-molecule compound protection.
• Potential coverage of pazopanib hydrochloride solid forms.
• Multiple possible claim layers across compound, composition, use, and process patents.
• High value of bioavailability and food-effect improvements.

Weaknesses

• Conventional tablet excipients are difficult to protect broadly.
• Generic manufacturers can substitute equivalent excipients.
• Method-of-use claims may be avoided through labeling carve-outs.
• A formulation patent may have limited commercial value if a simple immediate-release tablet remains bioequivalent and legally launchable.
• Solid-form claims can be challenged through alternative polymorphs, amorphous material, or different manufacturing routes.

The most defensible new patent position would combine a defined excipient system with measurable performance, such as improved dissolution under biorelevant conditions, reduced fed-versus-fasted variability, improved stability, or a clinically relevant exposure profile.

What commercial opportunities exist for pazopanib excipients?

1. Reduced food-effect tablet

A formulation that maintains comparable exposure under fed and fasted conditions could improve adherence and simplify prescribing. It would have value for both branded lifecycle management and a differentiated 505(b)(2) product.

The commercial case is strongest if the formulation provides a clinically meaningful reduction in exposure variability without requiring complex administration instructions.

2. Dose-flexible formulation

Lower-strength tablets, scored tablets, multiparticulates, or divisible dosage forms could support dose reduction for adverse-event management. Pazopanib treatment can require dose interruption or reduction, making dose flexibility commercially relevant.

A 100 mg or lower-strength product may compete through convenience rather than superior pharmacokinetics.

3. Dysphagia and feeding-tube delivery

A dispersible tablet, oral suspension, or granulated product could target oncology patients with swallowing limitations. The product would need validated tube compatibility and a reliable dose-recovery profile.

This opportunity has a stronger clinical rationale than a pediatric product because it addresses an identified administration problem in the treated population.

4. Improved manufacturing robustness

A co-processed excipient system could improve powder flow, reduce tablet weight, support direct compression, or reduce batch-to-batch dissolution variability. The commercial buyer would include generic manufacturers seeking lower manufacturing cost and fewer scale-up failures.

Potential value drivers include reduced granulation time, improved content uniformity, lower lubricant sensitivity, and improved tablet hardness without slower dissolution.

5. 505(b)(2) solubilized product

A lipid, amorphous dispersion, or nanosuspension product could seek approval based partly on existing pazopanib safety and efficacy data. This pathway is more expensive than a standard ANDA but can support differentiated claims and a separate commercial position.

6. Excipients for global supply

A simple, stable formulation that avoids specialized equipment may have value in emerging markets. The main requirements are humidity tolerance, low-cost raw materials, robust packaging, and compatibility with local manufacturing infrastructure.

Which companies are challenging pazopanib?

Generic competition is expected from companies that develop ANDA products for pazopanib hydrochloride tablets. The relevant competitive set includes established generic oncology suppliers, contract development and manufacturing organizations, and companies holding abbreviated approvals.

The most important competitive distinction is not the number of applicants but the timing and legal basis of each launch. A first-to-file Paragraph IV applicant may have an advantage over later applicants, while a later applicant with a non-infringing formulation may enter after patent expiry without relying on a contested formulation platform.

No biosimilar competition is relevant because pazopanib is a chemically synthesized small molecule rather than a biologic.

What patent litigation and settlement issues affect pazopanib?

Pazopanib litigation may involve infringement claims against ANDA applicants, challenges to compound or formulation patents, and disputes over the scope of carved-out labeling. Settlement terms can determine whether a generic launches before the asserted patent expiry, but those terms are not always fully public.

A commercial diligence review should examine:

• FDA Paragraph IV notifications.
• District court complaints and claim-construction orders.
• Inter partes review filings.
• Federal Circuit decisions.
• FDA tentative and final approvals.
• Authorized-generic arrangements.
• Settlement dates and permitted launch dates.
• Any competitive restrictions involving formulation suppliers.

The absence of a reported high-profile dispute does not establish freedom to operate. Patent families outside the Orange Book can still affect manufacturing processes, solid forms, or formulation technologies.

How does pazopanib compare with competing oral oncology drugs?

Product	Active ingredient	Primary formulation issue	Excipient opportunity
Votrient	Pazopanib hydrochloride	Low solubility and major food effect	Food-effect reduction, dispersion, liquid delivery
Sutent	Sunitinib malate	Solubility and capsule-based delivery	Improved dose flexibility and alternative solid forms
Inlyta	Axitinib	Low aqueous solubility	Nanocrystals, dispersion, wetting systems
Cabometyx	Cabozantinib	Complex exposure and tolerability management	Dose flexibility and modified release concepts
Nexavar	Sorafenib tosylate	Low solubility and food-related exposure	Solubilization and alternative delivery systems

Pazopanib has a particularly clear formulation opportunity because the food effect creates a direct administration burden. A technically successful excipient system can compete on predictability rather than only on cost.

Key Takeaways

• Pazopanib is a poorly soluble oral kinase inhibitor marketed as an immediate-release film-coated tablet.
• Votrient uses conventional tablet excipients, including microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate.
• The largest formulation weakness is the substantial increase in exposure with food.
• Amorphous solid dispersions, pH-modified systems, surfactants, nanocrystals, and lipid formulations are the main technical options.
• The strongest commercial opportunity is a formulation that reduces food-effect variability while remaining manufacturable and bioequivalent.
• Liquid, dispersible, or dose-flexible products could address swallowing difficulty and dose modification.
• Pazopanib has no biosimilar pathway; competition comes from ANDA generics and differentiated 505(b)(2) products.
• Compound, solid-form, formulation, and method-of-use patents must be assessed separately.
• Conventional excipient substitutions are usually easier to design around than claims tied to a defined dissolution, exposure, or stability outcome.
• A high-value patent position should link the excipient system to measurable pharmacokinetic or manufacturing performance.

FAQs About Pazopanib Excipient and Formulation Opportunities

Can pazopanib be formulated as an oral suspension?

Yes. An oral suspension is technically feasible, but development must address sedimentation, redispersibility, taste, stability, dose accuracy, and compatibility with feeding tubes. The product would likely require a differentiated regulatory and commercial rationale.

Does pazopanib require a solubilizer?

Not necessarily. Votrient uses a conventional immediate-release tablet, but a solubilizer may improve wetting and dissolution in an alternative formulation. The excipient must not create unacceptable tolerability, stability, or bioequivalence problems.

Is a pazopanib amorphous solid dispersion commercially attractive?

It can be attractive if it reduces food-effect variability or enables a smaller, more reliable dosage form. The main risks are recrystallization, moisture sensitivity, manufacturing complexity, and patent challenges.

Can a generic pazopanib use different excipients from Votrient?

Yes. An ANDA product generally may use different inactive ingredients if it meets applicable safety, quality, pharmaceutical-equivalence, and bioequivalence requirements. The substitute excipients must also comply with FDA inactive-ingredient and product-quality expectations.

What is the best excipient platform for a pazopanib lifecycle product?

The strongest platform is a stable solubilizing system that improves dissolution across gastrointestinal pH conditions and reduces the fed-versus-fasted exposure difference. An amorphous dispersion, nanocrystal, or carefully designed surfactant-polymer system could support that objective.

References

1. U.S. Food and Drug Administration. (2024). Votrient (pazopanib hydrochloride) tablets: Prescribing information.
2. U.S. Patent No. 6,258,812. (2001). Pyrimidine derivatives as kinase inhibitors. United States Patent and Trademark Office.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition.
4. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioavailability and bioequivalence studies submitted in support of abbreviated new drug applications.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, Votrient.